Clinical Trial Update: Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study to identify the optimal renoprotective dose of aliskiren in hypertensive patients with Type 2 diabetes an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 1, Phase 2 | Status: COMPLETED